Table 1.
Clinical characteristics of patients with MDS and control subjects.
| Characteristic | Low-risk group (n = 48) | High-risk group (n = 45) | Control (n = 20) |
|---|---|---|---|
| Sex, male/female, n | 28/20 | 26/19 | 12/8 |
| Median age (range), years | 47 (11–75) | 45 (12–77) | 45 (14–72) |
| Median WBC (range), count ×109 cells/L | 3.4 (2.2–9.8) | 2.8 (1.6–13.9) | 5.9 (4.2–10.0) |
| Median PLT count (range), ×109 cells/L | 103.5 (16–351) | 57 (6–155) | 244 (112–308) |
| Median HB level (range) g/L | 80 (45–120) | 77.5 (40–115) | 112 (105–127) |
| Median IPSS score (range) | 0.5 (0–1.0) | 2.5 (1.5–3.0) | N/A |
| WHO classification | N/A | ||
| RA | 23 | 0 | |
| RARS | 17 | 0 | |
| RCMD | 8 | 7 | |
| RAEB | 0 | 38 |
MDS, myelodysplastic syndromes; WBC, white blood cell; PLT, platelet; HB, hemoglobin; IPSS, International Prognostic Scoring System; N/A, not applicable; WHO, World Health Organization; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multiple dysplasia; RAEB, refractory anemia with excess blasts.